GE Healthcare AS Medical Diagnostics Norway Who are we today? What are our success criteria?
-
Upload
elissa-simms -
Category
Documents
-
view
215 -
download
2
Transcript of GE Healthcare AS Medical Diagnostics Norway Who are we today? What are our success criteria?
![Page 1: GE Healthcare AS Medical Diagnostics Norway Who are we today? What are our success criteria?](https://reader036.fdocuments.in/reader036/viewer/2022070308/551bf143550346c3588b65cb/html5/thumbnails/1.jpg)
GE Healthcare ASMedical Diagnostics Norway
Who are we today?What are our success criteria?
![Page 2: GE Healthcare AS Medical Diagnostics Norway Who are we today? What are our success criteria?](https://reader036.fdocuments.in/reader036/viewer/2022070308/551bf143550346c3588b65cb/html5/thumbnails/2.jpg)
2 /This is GE Healthcare
Who we are: GE business segments
Aviation
Energy
EnterpriseSolutions
Water
Oil & Gas
CommercialFinance
GE Money
CorporateTreasury
Transportation
Healthcare
TechnologyInfrastructure
EnergyInfrastructure
GECapital
NBCUniversal
GE is Imagination at Work - a diversified technology, media and financial services company focused on solving some of the world's toughest problems. With products and services ranging from aircraft engines, power generation, water processing and security technology to medical imaging, business and consumer financing, media content and industrial products, we serve customers in more than 100 countries and employ more than 320,000 people worldwide.
![Page 3: GE Healthcare AS Medical Diagnostics Norway Who are we today? What are our success criteria?](https://reader036.fdocuments.in/reader036/viewer/2022070308/551bf143550346c3588b65cb/html5/thumbnails/3.jpg)
3 /This is GE Healthcare
Broad solutions for healthcare
Medical Diagnostics
Electronic medical records
Diagnostic imaging &Surgery
Discovery tools
Integrated admin. & clinical
ClinicalSystems
Picture Archiving System (PACS)
Protein & cell sciences
Clinical tissue biomarkers
Broad-based Diagnostics
LifeSciences
InformationTechnology
![Page 4: GE Healthcare AS Medical Diagnostics Norway Who are we today? What are our success criteria?](https://reader036.fdocuments.in/reader036/viewer/2022070308/551bf143550346c3588b65cb/html5/thumbnails/4.jpg)
4 /This is GE Healthcare
GE Healthcare
•$17B global business unit of GE
•$1B+/year in R&D investment–Over 2,000 research scientists–Nearly 1,000 PhDs–Multiple disciplines–45 different nationalities
•44.000 employees
![Page 5: GE Healthcare AS Medical Diagnostics Norway Who are we today? What are our success criteria?](https://reader036.fdocuments.in/reader036/viewer/2022070308/551bf143550346c3588b65cb/html5/thumbnails/5.jpg)
5 /This is GE Healthcare
Medical Diagnostics (~4500 employees)•The only Pharmaceutical unit in GE
•World leader in contrast agents and nuclear medicine products for diagnostic imaging across all modalities.
![Page 6: GE Healthcare AS Medical Diagnostics Norway Who are we today? What are our success criteria?](https://reader036.fdocuments.in/reader036/viewer/2022070308/551bf143550346c3588b65cb/html5/thumbnails/6.jpg)
6 /This is GE Healthcare
GE Healthcare AS – Norwegian branch of Medical DiagnosticsMilestones
The exceptional R&D environment that has emerged in Norway since 1874 will continue to play an important role in the development of new products for diagnosis, treatment and prevention of disease. This position was continued with the merger between Nycomed and Amersham International in 1997 - further strengthened under GE Healthcare from 2004
Pharmacist Morten NyegaardFounder of Nyegaard & Co,later Nycomed, in 1874
Pharmacist Morten NyegaardFounder of Nyegaard & Co,later Nycomed, in 1874
Nycomed’s first X-ray contrast medium, a copyprep. reg.1934
Nycomed’s first X-ray contrast medium, a copyprep. reg.1934
Nycomed develops world’s first non-ionic X-ray contrast medium in collaboration with Professor Torsten Almén of Lund, Sweden
Nycomed develops world’s first non-ionic X-ray contrast medium in collaboration with Professor Torsten Almén of Lund, Sweden
Omnipaque, 2nd generation non-ionicX-ray contrast medium, for many years ranked among the top 10 pharma-ceutical products sold world-wide.
Omnipaque, 2nd generation non-ionicX-ray contrast medium, for many years ranked among the top 10 pharma-ceutical products sold world-wide.
![Page 7: GE Healthcare AS Medical Diagnostics Norway Who are we today? What are our success criteria?](https://reader036.fdocuments.in/reader036/viewer/2022070308/551bf143550346c3588b65cb/html5/thumbnails/7.jpg)
7 /This is GE Healthcare
GE Healthcare AS
• Total revenues (incl exports): $ 1,0 billion • In market sales: $15,5 million• R&D 55 $ (ex 5.11) 136’ $ (08’) ( approx. 1 mill $ 09’)• approx. 200 employees
GEHC total no of employees: 1300 - Largest Pharma player in Norway
Lindesnes site (Primary manuf. 350 employees)
Oslo site (Sec. manuf., R&D, 650 employees)
![Page 8: GE Healthcare AS Medical Diagnostics Norway Who are we today? What are our success criteria?](https://reader036.fdocuments.in/reader036/viewer/2022070308/551bf143550346c3588b65cb/html5/thumbnails/8.jpg)
8 /This is GE Healthcare
Key promoted brands
Launched 2000First agent to
identify Parkinson’s Disease
Launched 1996Myocardial perfusion
Launched 1993Non-ionic MRIAll disease areas
Launched 1982Global Gold standardAll disease areas
Launched 1993ONLY Iso-Osmolar
mediaAll disease areas
Product Description ~ Annual Rev $m
>500m
>700m
>300m
>180m
>40m
![Page 9: GE Healthcare AS Medical Diagnostics Norway Who are we today? What are our success criteria?](https://reader036.fdocuments.in/reader036/viewer/2022070308/551bf143550346c3588b65cb/html5/thumbnails/9.jpg)
9 /This is GE Healthcare
So what’s makes a success? (I)
•Key competences – focus
•Decisiveness (privately owned at the time)
•Available funding
•The right product area – niche(?)
•The right product opportunity - IPR
•Key competence - develop
![Page 10: GE Healthcare AS Medical Diagnostics Norway Who are we today? What are our success criteria?](https://reader036.fdocuments.in/reader036/viewer/2022070308/551bf143550346c3588b65cb/html5/thumbnails/10.jpg)
10 /This is GE Healthcare
So what’s makes a success? (II)
•Right strategy (build from strength)– Leverage partnerships
(Schering/Daiichi/Sterling) & local strength– Transition to own presence (Schering-Sterling) – Focus on core competencies (CM…)– Continuous improvements (Lindesnes/primary
production – retain competitiveness)– Long term R&D strategy and continuous
investments (build capacity + feed pipeline)– Business Dvlp – M&A
X
![Page 11: GE Healthcare AS Medical Diagnostics Norway Who are we today? What are our success criteria?](https://reader036.fdocuments.in/reader036/viewer/2022070308/551bf143550346c3588b65cb/html5/thumbnails/11.jpg)
11 /This is GE Healthcare
Predict
Gene Assay
MolecularDiagnostics
Predict & Prevent Disease …
Detect
ProteinIn Vitro(IVD)
Pinpoint
Imaging
Imaging, IVD
Track and Verify
MolecularImaging
Prevent/Treat
MolecularTherapeutics
The Future … Molecular Medicine
MolecularTherapeutics
MolecularImaging
MolecularDiagnostics
![Page 12: GE Healthcare AS Medical Diagnostics Norway Who are we today? What are our success criteria?](https://reader036.fdocuments.in/reader036/viewer/2022070308/551bf143550346c3588b65cb/html5/thumbnails/12.jpg)
12 /This is GE Healthcare
Diagnose and treat before symptoms appear
Provide treatments tailored to individual’s genetic makeup
Focusing on cancer, heart disease and Alzheimer's
Collaborating with leading pharmaceutical companies and medical researchers
GE in best position to grow and leverage
Molecular Medicine
![Page 13: GE Healthcare AS Medical Diagnostics Norway Who are we today? What are our success criteria?](https://reader036.fdocuments.in/reader036/viewer/2022070308/551bf143550346c3588b65cb/html5/thumbnails/13.jpg)
13 /This is GE Healthcare
Portfolio spans modalities and diseases
Cardiology
Oncology
Neurology
Urology
Optical Imaging
TargetedSPECT
PETMRI SPECTX-Ray/CT
Anatomy Function Perfusion Viability Metabolism
Contrast Media Molecular Imaging
![Page 14: GE Healthcare AS Medical Diagnostics Norway Who are we today? What are our success criteria?](https://reader036.fdocuments.in/reader036/viewer/2022070308/551bf143550346c3588b65cb/html5/thumbnails/14.jpg)
14 /This is GE Healthcare
Post GE – why Norway?
•Focus on core competencies (CM + MI) feed product pipeline•Continuous improvements (Lindesnes/primary production – maintain competitiveness)
Available competence – limitations Norway
Available funding need competitive environment (R&D/technology developments: incentives) – global competition
Norway need to stay competitive – do’s & don’ts:– Cost levels invest in high tech/focus on cost drivers– Funding develop incentives – establish competitive
advantages – commercialization is key– Competence education + “brain” import simplification– Do not create obstacles harmonized rules & regulations
![Page 15: GE Healthcare AS Medical Diagnostics Norway Who are we today? What are our success criteria?](https://reader036.fdocuments.in/reader036/viewer/2022070308/551bf143550346c3588b65cb/html5/thumbnails/15.jpg)
Takk!
Spørsmål?
![Page 16: GE Healthcare AS Medical Diagnostics Norway Who are we today? What are our success criteria?](https://reader036.fdocuments.in/reader036/viewer/2022070308/551bf143550346c3588b65cb/html5/thumbnails/16.jpg)
16 /This is GE Healthcare
What is Pharma?
• $650B global market• $500MM - $1B sales per year• Highly regulated industry from
development through marketing• General patent life ~ 20 yrs• Average drug development 10 – 15 yrs
at a cost of greater than $1B* • Generally thought of as encompassing
therapeutic drugs, both branded and generic
• Chronic administration
Therapeutics Diagnostics• $7B global market• Sub-segment of the pharmaceutical
industry (“specialty pharma”)• $50 - $200MM sales per year• Drugs used to aid in diagnostic
imaging procedures that highlight organs, tissues and processes in the body
• Acute administration• Only 2 products approved in past 10
years• POS ranges from 16% phase 1 to
50% phase 3*Includes costs of failed compounds
![Page 17: GE Healthcare AS Medical Diagnostics Norway Who are we today? What are our success criteria?](https://reader036.fdocuments.in/reader036/viewer/2022070308/551bf143550346c3588b65cb/html5/thumbnails/17.jpg)
17 /This is GE Healthcare
Fra Nyegaard & Co til GE Healthcare
1874 Morten Nyegaard, cand pharm
1890 Nyegaard & Co (Nyco)
1986 Nycomed AS
1992 Nycomed Imaging AS
1997 Nycomed Amersham Imaging AS
2001 Amersham Health AS
2004 GE Healthcare